Accéder au contenu
Merck
Toutes les photos(1)

Documents

B0470000

Benperidol

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]-piperidin-4-yl}-1,3-dihydro-benzimidazol-2-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H24FN3O2
Numéro CAS:
Poids moléculaire :
381.44
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

benperidol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

Clé InChI

FEBOTPHFXYHVPL-UHFFFAOYSA-N

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Benperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

S M Moerlein et al.
Nuclear medicine and biology, 22(6), 809-815 (1995-08-01)
[18F]Benperidol ([18F]BP), a positron-emitting analogue of the dopaminergic D2 antagonist benperidol, was evaluated as a radiopharmaceutical for use with positron emission tomography (PET). PET imaging of baboons after i.v. injection of [18F]BP indicated that the radiofluorinated ligand rapidly localized in
J Schröder et al.
Psychiatry research, 75(2), 115-123 (1997-11-14)
Recent studies have described a left lateralized striatal asymmetry of D2 dopamine receptors in male patients with schizophrenia. To replicate this finding and to explore its potential functional consequences, we investigated the D2 dopamine receptor system in 23 drug-naive patients
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Carlos Schönfeldt-Lecuona et al.
Journal of clinical psychopharmacology, 24(1), 97-98 (2004-01-08)
I Biryol et al.
Journal of pharmaceutical and biomedical analysis, 15(11), 1695-1701 (1997-07-01)
In this study two butyrophenones, droperidol and benperidol were voltammetrically investigated using platinum and specially activated glass carbon electrodes. The behaviours of the substance were investigated in various electrolyte solutions having different pH values and by different scan rates. As
J Schröder et al.
Fortschritte der Neurologie-Psychiatrie, 68 Suppl 1, S42-S45 (2000-07-25)
Animal and post mortem studies indicate that neuroleptic therapy may induce D2-dopamine receptor upregulation in the basal ganglia. To address this phenomenon in a clinical study, we investigated the D2-dopamine receptor binding in 15 DSM-III-R schizophrenics in the drug-naive state

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique